Response to Letter to the Editor Regarding : Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
| Errataetall: |
CommentOn: Adv Ther. 2019 Aug;36(8):2147-2160. - PMID 31140123 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Advances in therapy - 37(2020), 2 vom: 14. Feb., Seite 958-962 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Proskorovsky, Irina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4FR53SIF3A |
|---|
| Anmerkungen: |
Date Completed 20.04.2020 Date Revised 10.01.2021 published: Print-Electronic CommentOn: Adv Ther. 2019 Aug;36(8):2147-2160. - PMID 31140123 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-019-01169-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304397830 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304397830 | ||
| 003 | DE-627 | ||
| 005 | 20231225114911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-019-01169-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1014.xml |
| 035 | |a (DE-627)NLM304397830 | ||
| 035 | |a (NLM)31838711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Proskorovsky, Irina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to Letter to the Editor Regarding |b Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Adv Ther. 2019 Aug;36(8):2147-2160. - PMID 31140123 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a blinatumomab |2 NLM | |
| 650 | 7 | |a 4FR53SIF3A |2 NLM | |
| 650 | 7 | |a Inotuzumab Ozogamicin |2 NLM | |
| 650 | 7 | |a P93RUU11P7 |2 NLM | |
| 700 | 1 | |a Vandendries, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Pagé, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelleri, Joseph C |e verfasserin |4 aut | |
| 700 | 1 | |a Stelljes, Matthias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 37(2020), 2 vom: 14. Feb., Seite 958-962 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:2 |g day:14 |g month:02 |g pages:958-962 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-019-01169-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 2 |b 14 |c 02 |h 958-962 | ||